ADCTNYSEPharmaceutical PreparationsFiscal year ends December 31
ADC Therapeutics SA
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.44+0.04 (+2.86%)
Close on Oct 19, 2026
- Market cap
- $223.22M
- P/E (TTM)
- –
- Dividend yield
- –
ADC Therapeutics SA revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Product revenues, net | $73.55M | $69.28M | $69.06M | $74.91M | – | – | – | 90.4% | +6.2% |
| License revenues and royalties | $7.81M | $1.56M | – | – | – | – | – | 9.6% | +401.3% |
| License revenues | $5.00M | $0 | $0 | $135.00M | – | – | – | 6.1% | – |
| Royalties | $2.81M | $1.56M | $498.00K | $0 | – | – | – | 3.4% | +80.2% |
| Product Revenue | – | – | – | $74.91M | $33.92M | $0 | $0 | – | – |
| Contract Revenue | – | – | – | $135.00M | $0 | $0 | $2.34M | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| United States | $73.55M | $69.28M | $69.06M | $74.91M | – | – | – | 90.4% | +6.2% |
| EMEA | $7.81M | $1.56M | $498.00K | $105.00M | – | – | – | 9.6% | +401.3% |
| Japan | – | – | $0 | $30.00M | – | – | – | – | – |
From the segment and revenue-disaggregation notes of ADC Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.